abstract |
The present invention relates to methods and pharmaceutical compositions for the treatment of Th17 mediated diseases. In particular, the invention relates to a method of treating a Th17 mediated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CD95 antagonist. |